Synthesis and biological evaluation of benzochromenopyrimidinones as cholinesterase inhibitors and potent antioxidant, non-hepatotoxic agents for Alzheimer's disease

Molecules

Volumn 21, Issue 5, 2016, Pages

  Dgachi, Youssef ^a   Bautista Aguilera, Oscar M ^b   Benchekroun, Mohamed ^b,h   Martin, Hélène ^c   Bonet, Alexandre ^c   Knez, Damijan ^d   Godyń, Justyna ^e   Malawska, Barbara ^e   Gobec, Stanislav ^d   Chioua, Mourad ^f   Janockova, Jana ^g   Soukup, Ondrej ^g   Chabchoub, Fakher ^a   Marco Contelles, José ^f   Ismaili, Lhassane ^b  

^a University of Sfax   (Tunisia)

^b University Hospital of Besançon   (France)

^c France   (France)

^d UNIVERSITY OF LJUBLJANA   (Slovenia)

^e JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^f INSTITUTO DE QUÍMICA ORGÁNICA GENERAL   (Spain)

^g UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^h CNRS   (France)

Author keywords

Alzheimer's disease; Antioxidants; Cholinesterase inhibitors; Hepatotoxicity; Multicomponent reactions; Multitarget directed ligands; Quinazolinones

Indexed keywords

ANTIOXIDANT; CHOLINESTERASE INHIBITOR;

ALZHEIMER DISEASE; DRUG EFFECT; HUMAN; IC50; LIVER; SPECTROSCOPY; SYNTHESIS;

ALZHEIMER DISEASE; ANTIOXIDANTS; CHOLINESTERASE INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; LIVER; SPECTRUM ANALYSIS;

EID: 84973646377     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules21050634     Document Type: Article

References (31)

1. World Alzheimer Report 2015. Available online: http://www.worldalzreport2015.org/ (accessed on 3 February 2016).
2. Liu, L.; Luo, S.; Zeng, L.; Wang, W.; Yuan, L.; Jian, X. Degenerative alterations in noradrenergic neurons of the locus coeruleus in Alzheimer's disease. Neural Regen. Res. 2013, 8, 2249-2255.
3. Mesulam, M.-M. Cholinergic circuitry of the human nucleus basalis and its fate in Alzheimer's disease. J. Comp. Neurol. 2013, 521, 4124-4144.
4. Zarow, C.; Lyness, S.A.; Mortimer, J.A.; Chui, H.C. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in alzheimer and parkinson diseases. Arch. Neurol. 2003, 60, 337-341.
5. Praticò, D.; Sung, S. Lipid peroxidation and oxidative imbalance: Early functional events in Alzheimer's disease. J. Alzheimers Dis. JAD 2004, 6, 171-175.
6. Yan, M.H.; Wang, X.; Zhu, X. Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease. Free Radic. Biol. Med. 2013, 62, 90-101.
7. Greenough, M.A.; Camakaris, J.; Bush, A.I. Metal dyshomeostasis and oxidative stress in Alzheimer's disease. Neurochem. Int. 2013, 62, 540-555.
8. Candore, G.; Bulati, M.; Caruso, C.; Castiglia, L.; Colonna-Romano, G.; di Bona, D.; Duro, G.; Lio, D.; Matranga, D.; Pellicanò, M.; et al. Inflammation, cytokines, immune response, apolipoprotein E, cholesterol, and oxidative stress in Alzheimer disease: Therapeutic implications. Rejuvenation Res. 2010, 13, 301-313.
9. Bond, M.; Rogers, G.; Peters, J.; Anderson, R.; Hoyle, M.; Miners, A.; Moxham, T.; Davis, S.; Thokala, P.; Wailoo, A.; et al. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): A systematic review and economic model. Health Technol. Assess. 2012, 16.
10. Wilkinson, D.; Wirth, Y.; Goebel, C. Memantine in Patients with Moderate to Severe Alzheimer's Disease: Meta-Analyses Using Realistic Definitions of Response. Dement. Geriatr. Cogn. Disord. 2014, 37, 71-85.
11. Watkins, P.B.; Zimmerman, H.J.; Knapp, M.J.; Gracon, S.I.; Lewis, K.W. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994, 271, 992-998.
12. Bolea, I.; Juárez-Jiménez, J.; de los Ríos, C.; Chioua, M.; Pouplana, R.; Luque, F.J.; Unzeta, M.; Marco-Contelles, J.; Samadi, A. Synthesis, Biological Evaluation, and Molecular Modeling of Donepezil and N-[(5-(Benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine Hybrids as New Multipotent Cholinesterase/Monoamine Oxidase Inhibitors for the Treatment of Alzheimer's Disease. J. Med. Chem. 2011, 54, 8251-8270.
13. Samadi, A.; Chioua, M.; Bolea, I.; de los Ríos, C.; Iriepa, I.; Moraleda, I.; Bastida, A.; Esteban, G.; Unzeta, M.; Gálvez, E.; et al. Synthesis, biological assessment and molecular modeling of new multipotent MAO and cholinesterase inhibitors as potential drugs for the treatment of Alzheimer's disease. Eur. J. Med. Chem. 2011, 46, 4665-4668.
14. Ismaili, L.; Refouvelet, B.; Benchekroun, M.; Brogi, S.; Brindisi, M.; Gemma, S.; Campiani, G.; Filipic, S.; Agbaba, D.; Esteban, G.; et al. Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease. Prog. Neurobiol. 2016.
15. Decker, M. Novel inhibitors of acetyl- and butyrylcholinesterase derived from the alkaloids dehydroevodiamine and rutaecarpine. Eur. J. Med. Chem. 2005, 40, 305-313.
16. Huang, G.; Kling, B.; Darras, F.H.; Heilmann, J.; Decker, M. Identification of a neuroprotective and selective butyrylcholinesterase inhibitor derived from the natural alkaloid evodiamine. Eur. J. Med. Chem. 2014, 81, 15-21.
17. Darras, F.H.; Wehle, S.; Huang, G.; Sotriffer, C.A.; Decker, M. Amine substitution of quinazolinones leads to selective nanomolar AChE inhibitors with "inverted" binding mode. Bioorg. Med. Chem. 2014, 22, 4867-4881.
18. Benchekroun, M.; Ismaili, L.; Pudlo, M.; Luzet, V.; Gharbi, T.; Refouvelet, B.; Marco-Contelles, J. Donepezil-ferulic acid hybrids as anti-Alzheimer drugs. Future Med. Chem. 2015, 7, 15-21.
19. Benchekroun, M.; Bartolini, M.; Egea, J.; Romero, A.; Soriano, E.; Pudlo, M.; Luzet, V.; Andrisano, V.; Jimeno, M.-L.; López, M.G.; et al. Novel Tacrine-Grafted Ugi Adducts as Multipotent Anti-Alzheimer Drugs: A Synthetic Renewal in Tacrine-Ferulic Acid Hybrids. ChemMedChem 2015, 10, 523-539.
20. Ou, B.; Hampsch-Woodill, M.; Prior, R.L. Development and validation of an improved oxygen radical absorbance capacity assay using fluorescein as the fluorescent probe. J. Agric. Food Chem. 2001, 49, 4619-4626.
21. Dávalos, A.; Gómez-Cordovés, C.; Bartolomé, B. Extending Applicability of the Oxygen Radical Absorbance Capacity (ORAC-Fluorescein) Assay. J. Agric. Food Chem. 2004, 52, 48-54.
22. Fang, L.; Kraus, B.; Lehmann, J.; Heilmann, J.; Zhang, Y.; Decker, M. Design and synthesis of tacrine-ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates. Bioorg. Med. Chem. Lett. 2008, 18, 2905-2909.
23. Ellman, G.L.; Courtney, K.D.; Andres, V.; Feather-Stone, R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 1961, 7, 88-95.
24. Decker, M.; Krauth, F.; Lehmann, J. Novel tricyclic quinazolinimines and related tetracyclic nitrogen bridgehead compounds as cholinesterase inhibitors with selectivity towards butyrylcholinesterase. Bioorg. Med. Chem. 2006, 14, 1966-1977.
25. Esquivias-Pérez, M.; Maalej, E.; Romero, A.; Chabchoub, F.; Samadi, A.; Marco-Contelles, J.; Oset-Gasque, M.J. Nontoxic and neuroprotective β-naphthotacrines for Alzheimer's disease. Chem. Res. Toxicol. 2013, 26, 986-992.
26. Di, L.; Kerns, E.H.; Fan, K.; McConnell, O.J.; Carter, G.T. High throughput artificial membrane permeability assay for blood-brain barrier. Eur. J. Med. Chem. 2003, 38, 223-232.
27. Lemes, L.F.N.; de Andrade Ramos, G.; de Oliveira, A.S.; da Silva, F.M.R.; de Castro Couto, G.; da Silva Boni, M.; Guimarães, M.J.R.; Souza, I.N.O.; Bartolini, M.; et al. Cardanol-derived AChE inhibitors: Towards the development of dual binding derivatives for Alzheimer's disease. Eur. J. Med. Chem. 2016, 108, 687-700.
28. Cornish-Bowden, A. A Simple graphical method for determining the inhibition constants of mixed, uncompetitive and non-competitive inhibitors (Short Communication). Biochem. J. 1974, 137, 143-144.
29. Silverman, R.B. The Organic Chemistry of Enzyme-catalyzed Reactions; Academic Press: San Diego, CA, USA, 2000.
30. Sugano, K.; Hamada, H.; Machida, M.; Ushio, H. High Throughput Prediction of Oral Absorption: Improvement of the Composition of the Lipid Solution Used in Parallel Artificial Membrane Permeation Assay. J. Biomol. Screen. 2001, 6, 189-196.
31. Wohnsland, F.; Faller, B. High-Throughput Permeability pH Profile and High-Throughput Alkane/Water log P with Artificial Membranes. J. Med. Chem. 2001, 44, 923-930.